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Abstract
In a recent study published in BMC Medicine, Singh Ospina and colleagues outlined the important gaps between
ongoing research and research needs in the field of endocrinology. Many recommendations from clinical practice
guidelines are based on a low level of evidence, thereby resulting in research gaps. Despite the publication of
around 25,000 randomized controlled trials each year, ongoing research does not cover most of these gaps. In
contrast, trials are planned when sufficient data are already available for decision making, which results in redundant
research and exposes patients to unnecessary risks. This lack of prioritization contributes to the enormous problem of
waste in research. A systematic approach to accumulate the available body of evidence is necessary to determine
when we have sufficient evidence and when we have knowledge gaps, defined as research questions with no or a low
level of evidence available. Systematic registration of research gaps and their prioritization may help to organize future
research. Some initiatives exist, but they need to be generalized.
Please see related research: http://www.biomedcentral.com/1741-7015/13/187
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Background
Waste related to poor planning and prioritization
of research
In 2009, Chalmers and Glasziou highlighted the enor-
mous problem of waste in research, estimating that up
to 85 % of research investment is wasted [1]. Waste oc-
curs at all stages of research [2–7] and particularly af-
fects planning and prioritization. We have increasing
evidence that many trials address low-priority questions
that are poorly related to the burden of disease [8] and
patient or physician needs [9, 10], do not address
patient-important outcomes [11] or use an inadequate
comparator. For example, in rheumatology, few trials
compare biologically active drugs against each other;
comparisons against placebo represent 80 % of trials reg-
istered at ClinicalTrials.gov [12]. This lack of head-to-
head trials does not allow for answering the pragmatic
question raised by patients and their physicians: for this
particular disease, which treatment is most effective?
Also, it exposes patients to unnecessary risks [12, 13].
Last but not least, trials are frequently planned regard-
less of the existing evidence. More than 50 % of trial
protocols do not refer to systematic reviews [14]. Many
trials are planned when sufficient data are already avail-
able for decision making, which results in redundant re-
search and exposes patients to unnecessary risks [3]. In
contrast, trials are not planned when they are needed to
fill research gaps, as highlighted by Singh Ospina and
colleagues in a recent study published in BMC Medicine
[15]. The authors defined research gaps as clinical ques-
tions with a very low level of evidence according to the
Grading of Recommendations Assessment, Development
and Evaluation (GRADE) approach from clinical practice
guidelines [15].
The worrying proportion of clinical practice guidelines
based on a poor level of evidence
In many clinical practice guidelines, few of the recom-
mendations are based on high-level evidence [16–18].
For example, a 2009 study published in JAMA showed
that 11 % of the recommendations in clinical practice
guidelines from the American College of Cardiology
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(ACC) and the American Heart Association (AHA) were
considered to be based on a high level of evidence [18].
Identifying clinical questions for which only low-level
evidence is available should, in theory, help in planning
future clinical trials focusing on these areas. Neverthe-
less, a study evaluating practice guidelines from the
Infectious Diseases Society of America showed no im-
provement in proportion of recommendations with a
high level of evidence over time [17]. It is very worrying
that, despite the publication of around 25,000 random-
ized controlled trials each year, clinical practice guide-
lines continue to rely mostly on a poor level of evidence,
with potentially serious consequences for patient care
[19]. Singh Ospina and colleagues used ClinicalTrials.gov
to assess the response in terms of new, active studies
conducted for research questions with a very low quality
of evidence according to the Endocrine Society clinical
practice guidelines [15]. The authors found active studies
for only one of five recommendations, which suggests
that ongoing research does not sufficiently adapt to fill
knowledge gaps in endocrinology.
Identifying gaps to decrease waste
The research community is becoming increasingly con-
cerned by these issues. We need to add incremental
value to existing evidence by a better connection to
future research. A first step is to systematically identify
research gaps. As outlined by Singh Ospina and col-
leagues, clinical practice guidelines could be helpful. In
the same way, systematic reviews, by synthesizing the
available body of evidence, have a key role to play. The
Cochrane Collaboration clearly recommends that review
authors systematically comment on the need for further
research in a separate section of the review, called
“Implications for research” [20]. Then, a second step
would be to record research gaps. Some initiatives
already exist. The UK Database of Uncertainties about
the Effects of Treatments (UK DUETs), established by
the National Institute for Health and Care Excellence
(NICE), publishes treatment uncertainties reported by
patients and clinicians and derived from research recom-
mendations and systematic reviews [21]. The Agency for
Health Research and Quality (AHRQ) has developed an
approach to identify and prioritize future research needs
to be used by researchers and funders to help improve
the body of comparative effectiveness evidence that
would be useful for decision makers [22]. However, there
is not enough information about these burgeoning initia-
tives. Nothing is done to facilitate the registration of re-
search gaps from different resources and there is no
particular incentive for review authors and those of clin-
ical practice guidelines to do so. A joint initiative to
centralize registration of gaps in a simple and com-
prehensible way would be very helpful to enhance
communication between researchers, physicians and
funders. Finally, the response in terms of new active stud-
ies conducted should be monitored to assess the adequacy
between ongoing research and knowledge gaps. With the
requirement to register trials at ClinicalTrials.gov or in
other registries, assessing the clinical trial enterprise and
monitoring whether ongoing research fits with research
needs has become easier.
Conclusions
Better prioritization of future research is necessary to in-
crease research value in a context of limited human and
monetary resources. Some initiatives exist to register
and prioritize research gaps. Such efforts should be en-
couraged and generalized to realign future studies with
the existing body of evidence.
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